These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37391075)

  • 1. Ablative Radioembolization of a Synchronous Renal Cell Carcinoma and Hepatocellular Carcinoma.
    McGregor H; Laidlaw G; Johnson G
    J Vasc Interv Radiol; 2023 Oct; 34(10):1847-1849. PubMed ID: 37391075
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioembolization of renal cell carcinoma using yttrium-90 microspheres.
    Hamoui N; Gates VL; Gonzalez J; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2013 Feb; 24(2):298-300. PubMed ID: 23369565
    [No Abstract]   [Full Text] [Related]  

  • 3. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.
    Salem R; Mazzaferro V; Sangro B
    Hepatology; 2013 Dec; 58(6):2188-97. PubMed ID: 23512791
    [No Abstract]   [Full Text] [Related]  

  • 4. Transarterial Radioembolization Ought Not to Borrow Future Liver Function from Patients with Hepatocellular Carcinoma. But Does It?
    Sangro B; Argemí J
    J Vasc Interv Radiol; 2023 Jun; 34(6):976-977. PubMed ID: 36787816
    [No Abstract]   [Full Text] [Related]  

  • 5. How to Prepare a Patient for Transarterial Radioembolization? A Practical Guide.
    Denys A; Pracht M; Duran R; Guiu B; Adib S; Boubaker A; Bize P
    Cardiovasc Intervent Radiol; 2015 Aug; 38(4):794-805. PubMed ID: 25828724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
    Ahmed AF; Samreen N; Grajo JR; Zendejas I; Sistrom CL; Collinsworth A; Esnakula A; Shah JL; Cabrera R; Geller BS; Toskich BB
    Abdom Radiol (NY); 2018 Jul; 43(7):1825-1836. PubMed ID: 29052747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of Hepatocellular Carcinoma Response After
    Semaan S; Makkar J; Lewis S; Chatterji M; Kim E; Taouli B
    AJR Am J Roentgenol; 2017 Nov; 209(5):W263-W276. PubMed ID: 29072955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
    Wehrenberg-Klee E; Gandhi RT; Ganguli S
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):70-73. PubMed ID: 31079713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-Arterial Radioembolization for Hepatocellular Carcinoma.
    Sacco R; Giorgi L; Fornaro L; Bargellini I
    Dig Dis; 2015 Sep; 33(5):661-7. PubMed ID: 26398498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
    Hickey RM; Lewandowski RJ; Salem R
    Semin Nucl Med; 2016 Mar; 46(2):105-8. PubMed ID: 26897714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist.
    Toskich BB; Liu DM
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):100-111. PubMed ID: 31079706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invited commentary.
    Salem R
    J Vasc Interv Radiol; 2011 Oct; 22(10):1362-3. PubMed ID: 21961980
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invited Commentary on "Single-Session Ablative Transarterial Radioembolization for Patients With Hepatocellular Carcinoma to Streamline Care: An Initial Experience".
    Ezponda A; Rodríguez-Fraile M
    Cardiovasc Intervent Radiol; 2024 Sep; 47(9):1246-1247. PubMed ID: 39160357
    [No Abstract]   [Full Text] [Related]  

  • 15. Ablative Transarterial Radioembolization of a Parasitized Adrenal Artery for the Treatment of Hepatocellular Carcinoma.
    Vidal LLC; Frey GT; Ritchie C; Lewis A; Paz-Fumagalli R; McKinney M; Toskich BB
    J Vasc Interv Radiol; 2019 Mar; 30(3):473-476. PubMed ID: 30819498
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium 90 Radioembolization for Hepatocellular Carcinoma.
    Howerton L
    Radiol Technol; 2021 Nov; 93(2):197-215. PubMed ID: 34728580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma.
    Burrel M; Bermúdez P; Forner González A
    Rev Esp Enferm Dig; 2022 Apr; 114(4):195-197. PubMed ID: 35315679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superselective yttrium-90 radioembolization for hepatocellular carcinoma in high-risk cases: another tool in the toolbox.
    Brown KT
    J Vasc Interv Radiol; 2014 Jul; 25(7):1073-4. PubMed ID: 24968727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.